Eltrombopag is well tolerated but provides no additional benefit in the treatment of canine primary immune-mediated thrombocytopenia
This study provided evidence that eltrombopag may be safely incorporated into immunosuppressive regimens for canine pITP; however, its clinical benefit remains uncertain. Further research is required to determine its role in optimizing treatment for ITP in dogs.
Authors
- S. Lee
- J.-Y. Han
- Mi Kyung Park (ORCID: https://orcid.org/0000-0002-2252-293X)
- Jeong‐Min Lee (ORCID: https://orcid.org/0000-0003-2920-7171)
- Kun‐Ho Song (ORCID: https://orcid.org/0000-0001-8478-2035)
- So‐Young Park (ORCID: https://orcid.org/0000-0002-5224-3077)
- Yeon Ju Kim
Institutions
- Chungnam National University (KR)
- Korea Animal Medical Center
Publication Details
- Journal
- Journal of the American Veterinary Medical Association
- Published
- 2025-10-29
- DOI
- https://doi.org/10.2460/javma.25.07.0483
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00